nach oben

Erschienen in:

04.01.2018 | Original Article

Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients

verfasst von: Akira Hachiya, Norimoto Kobayashi, Satoshi Matsuzaki, Yusuke Takeuchi, Yohei Akazawa, Tomonari Shigemura, Noriko Motoki, Junya Masumoto, Kazunaga Agematsu

Erschienen in: Clinical Rheumatology | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Infliximab (IFX) is effective for treatment of refractory Kawasaki disease (KD). However, the precise mechanisms and biomarkers for IFX efficacy are unknown. We tried to evaluate the effect and response to IFX therapy by measuring serum cytokine levels. Twenty-nine children with KD who had been resistant to two courses of high-dose intravenous immunoglobulin were enrolled and treated with IFX. Plasma samples were analyzed for cytokines before and after IFX administration. Serum levels of interleukin-6, granulocyte colony-stimulating factor (G-CSF), interferon-gamma-induced monokine, interferon-gamma inducible protein 10 (IP-10), monocyte chemotactic protein 1, and soluble tumor necrosis factor-alpha receptor (sTNFR) 1 and 2 were significantly elevated before IFX treatment, but promptly decreased after the administration. The pre-treatment G-CSF and sTNFR1 levels in non-responders to IFX were significantly higher than in responders, who were defined as patients who defervesce (< 37.5 °C). After IFX administration, elevated cytokines declined to normal ranges in responders, but in non-responsive group, G-CSF and sTNFR1 remained elevated without failing to normal levels. IFX treatment significantly reduced the levels of serum cytokines, chemokines, and sTNFRs in refractory KD. G-CSF and sTNFR1 may be indicators predictive of poor response to IFX.

Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 16(3):178–222PubMed

Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T (1984) High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2(8411):1055–1058CrossRefPubMed

Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, American Academy of Pediatrics (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110(17):2747–2771. https://doi.org/10.1161/01.CIR.0000145143.19711.78 CrossRefPubMed

Wallace CA, French JW, Kahn SJ, Sherry DD (2000) Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105(6):E78. https://doi.org/10.1542/peds.105.6.e78 CrossRefPubMed

Sonoda K, Mori M, Hokosaki T, Yokota S (2014) Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr 164(5):1128–1132. https://doi.org/10.1016/j.jpeds.2014.01.020 CrossRefPubMed

Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T et al (2012) Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 39(4):864–867. https://doi.org/10.3899/jrheum.110877 CrossRefPubMed

Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW (2011) Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 158(4):644–649. https://doi.org/10.1016/j.jpeds.2010.10.012 CrossRefPubMed

Song MS, Lee SB, Sohn S, JH O, Yoon KL, Han JW, Kim CH (2010) Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J 40(7):334–338. https://doi.org/10.4070/kcj.2010.40.7.334 CrossRefPubMedPubMedCentral

Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS et al (2008) Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2153:833–838CrossRef

10.

Burns JC, Shimizu C, Gonzalez E, Kulkarni H, Patel S, Shike H, Sundel RS, Newburger JW, Ahuja SK (2005) Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis 192(2):344–349. https://doi.org/10.1086/430953 CrossRefPubMedPubMedCentral

11.

Chen SY, Wan L, Huang YC, Sheu JJ, Lan YC, Lai CH et al (2009) Interleukin-18 gene 105A/C genetic polymorphism is associated with the susceptibility of Kawasaki disease. J Clin Lab Anal 23(2):71–76. https://doi.org/10.1002/jcla.20292 CrossRefPubMed

12.

Kim DS (1992) Serum interleukin-6 in Kawasaki disease. Yonsei Med J 33(2):183–188. https://doi.org/10.3349/ymj.1992.33.2.183 CrossRefPubMed

13.

Matsubara T, Furukawa S, Yabuta K (1990) Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 56(1):29–36. https://doi.org/10.1016/0090-1229(90)90166-N CrossRefPubMed

14.

Asano T, Ogawa S (2000) Expression of monocyte chemoattractant protein-1 in Kawasaki disease: the anti-inflammatory effect of gamma globulin therapy. Scand J Immunol 51(1):98–103. https://doi.org/10.1046/j.1365-3083.2000.00650.x CrossRefPubMed

15.

Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K (1994) Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 124(5):721–725. https://doi.org/10.1016/S0022-3476(05)81361-7 CrossRefPubMed

16.

Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M (2008) Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol 122(5):1008–1013. https://doi.org/10.1016/j.jaci.2008.09.011 CrossRefPubMed

17.

Ko TM, Kuo HC, Chang JS, Chen SP, Liu YM, Chen HW, Tsai FJ, Lee YC, Chen CH, Wu JY, Chen YT (2015) CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease. Circ Res 116(5):876–883. https://doi.org/10.1161/CIRCRESAHA.116.305834 CrossRefPubMed

18.

Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD (1999) The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 162(6):3549–3558PubMed

19.

Cassatella MA, Gasperini S, Calzetti F, Bertagnin A, Luster AD, McDonald PP (1997) Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol 27(1):111–115. https://doi.org/10.1002/eji.1830270117 CrossRefPubMed

20.

Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184(3):963–969. https://doi.org/10.1084/jem.184.3.963 CrossRefPubMed

21.

Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, Aikawa E, Moore KJ, Luster AD, Gerszten RE (2006) Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 113(19):2301–2312. https://doi.org/10.1161/CIRCULATIONAHA.105.605121 CrossRefPubMed

22.

Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, Ishii M, Harada K, Kawasaki Disease Research Committee (2005) Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 47(2):232–234. https://doi.org/10.1111/j.1442-200x.2005.02033.x CrossRefPubMed

23.

Feng S, Yadav SK, Gao F, Yi Q (2015) Plasma levels of monokine induced by interferon-gamma/chemokine (C-X-X motif) ligand 9, thymus and activation-regulated chemokine/chemokine (C-C motif) ligand 17 in children with Kawasaki disease. BMC Pediatr 15(1):109. https://doi.org/10.1186/s12887-015-0424-6 CrossRefPubMedPubMedCentral

24.

Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y (2013) Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum 65(3):805–814. https://doi.org/10.1002/art.37815 CrossRefPubMed

25.

Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, Watanabe K, Watanabe S, Uese K, Kanegane H, Origasa H, Ichida F, Roth J, Miyawaki T, Saji T (2009) Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 65(6):696–701. https://doi.org/10.1203/PDR.0b013e31819ed68d CrossRefPubMed

26.

Shigemura T, Yamazaki T, Hara Y, JN O, Stevens AM, Ochs HD et al (2011) Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Pediatr Rheumatol Online J 9(1):15. https://doi.org/10.1186/1546-0096-9-15 CrossRefPubMedPubMedCentral

27.

Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76(6):959–962. https://doi.org/10.1016/0092-8674(94)90372-7 CrossRefPubMed

28.

Lantz M, Malik S, Slevin ML, Olsson I (1990) Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2(6):402–406. https://doi.org/10.1016/1043-4666(90)90048-X CrossRefPubMed

29.

Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113(22):2606–2612. https://doi.org/10.1161/CIRCULATIONAHA.105.592865 CrossRefPubMed

30.

Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T (2006) Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149(2):237–240. https://doi.org/10.1016/j.jpeds.2006.03.050 CrossRefPubMed

31.

Tang Y, Yan W, Sun L, Huang J, Qian W, Ding Y, Lv H (2016) Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population. Clin Rheumatol 35(11):2771–2776. https://doi.org/10.1007/s10067-016-3370-2 CrossRefPubMed

32.

Gallo A, Saad A, Ali R, Dardik A, Tellides G, Geirsson A (2012) Circulating interferon-gamma-inducible Cys-X-Cys chemokine receptor 3 ligands are elevated in humans with aortic aneurysms and Cys-X-Cys chemokine receptor 3 is necessary for aneurysm formation in mice. J Thorac Cardiovasc Surg 143(3):704–710. https://doi.org/10.1016/j.jtcvs.2011.08.036 CrossRefPubMed

Titel: Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients
verfasst von: Akira Hachiya
Norimoto Kobayashi
Satoshi Matsuzaki
Yusuke Takeuchi
Yohei Akazawa
Tomonari Shigemura
Noriko Motoki
Junya Masumoto
Kazunaga Agematsu
Publikationsdatum: 04.01.2018
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 7/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3952-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Nierenkarzinom | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2018

Decreased IgG4 ACPA levels in responders and increased CD1c+ classical dendritic cells in non-responders of patients with rheumatoid arthritis under therapy

Variation in pain related to systemic lupus erythematosus (SLE): a 7-year follow-up study

Influence of the different “patient global assessment” formulations on disease activity score by different indices in rheumatoid arthritis

Response to ‘Ultrasound characterization of cutaneous ulcers in systemic sclerosis’

Advances in the diagnosis and treatment of Sjogren’s syndrome

Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Update Innere Medizin